{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:17:13Z","timestamp":1791213433170,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00277-018-3497-0","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T19:56:11Z","timestamp":1537473371000},"page":"159-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Neurologic adverse events in patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors"],"prefix":"10.1007","volume":"98","author":[{"given":"Anthony S.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsis","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"issue":"3","key":"3497_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"SM Richards","year":"2007","unstructured":"Fielding AK, Richards SM, Chopra R, Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI, Franklin IM, AK MM, Tallman MS, Rowe JM, Goldstone AH, Medical Research Council of the United Kingdom Adult ALLWP, Eastern Cooperative Oncology G (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109(3):944\u2013950. https:\/\/doi.org\/10.1182\/blood-2006-05-018192","journal-title":"Blood"},{"issue":"10","key":"3497_CR2","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N Gokbuget","year":"2012","unstructured":"Gokbuget N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, Schaich M, Schwartz S, Serve H, Starck M, Stelljes M, Stuhlmann R, Viardot A, Wendelin K, Freund M, Hoelzer D, German Multicenter Study Group for Adult Acute Lymphoblastic L (2012) Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120(10):2032\u20132041. https:\/\/doi.org\/10.1182\/blood-2011-12-399287","journal-title":"Blood"},{"issue":"11","key":"3497_CR3","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1002\/cncr.23919","volume":"113","author":"S O'Brien","year":"2008","unstructured":"O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186\u20133191. https:\/\/doi.org\/10.1002\/cncr.23919","journal-title":"Cancer"},{"issue":"5891","key":"3497_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmuller G, Reinhardt C, Baeuerle PA, Kufer P (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891):974\u2013977. https:\/\/doi.org\/10.1126\/science.1158545","journal-title":"Science"},{"issue":"1","key":"3497_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16(1):57\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(14)71170-2","journal-title":"Lancet Oncol"},{"issue":"S1","key":"3497_CR6","first-page":"S149","volume":"101","author":"MS Topp","year":"2016","unstructured":"Topp MS, Stein A, G\u00f6kbuget N, Fielding A, Schuh A, Maria Ribera Santasusana J, Wei J, Dombret H, Fo\u00e0 R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Kantarjian H (2016) Blinatumomab improved overall survival in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Haematologica 101(S1):S149","journal-title":"Haematologica"},{"issue":"36","key":"3497_CR7","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, Reichle A, Horst HA, Bruggemann M, Wessiepe D, Holland C, Alekar S, Mergen N, Einsele H, Hoelzer D, Bargou RC (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134\u20134140. https:\/\/doi.org\/10.1200\/JCO.2014.56.3247","journal-title":"J Clin Oncol"},{"issue":"10","key":"3497_CR8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, Hess G, Kallert S, Mackensen A, Rupertus K, Kanz L, Libicher M, Nagorsen D, Zugmaier G, Klinger M, Wolf A, Dorsch B, Quednau BD, Schmidt M, Scheele J, Baeuerle PA, Leo E, Bargou RC (2016) Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34(10):1104\u20131111. https:\/\/doi.org\/10.1200\/JCO.2014.59.1586","journal-title":"J Clin Oncol"},{"issue":"11","key":"3497_CR9","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC (2016) Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma. Blood 127(11):1410\u20131416. https:\/\/doi.org\/10.1182\/blood-2015-06-651380","journal-title":"Blood"},{"issue":"10","key":"3497_CR10","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40262-016-0405-4","volume":"55","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S (2016) Blinatumomab, a bispecific T-cell engager (BiTE(R)) for CD-19 targeted cancer immunotherapy: clinical pharmacology and its implications. Clin Pharmacokinet 55(10):1271\u20131288. https:\/\/doi.org\/10.1007\/s40262-016-0405-4","journal-title":"Clin Pharmacokinet"},{"key":"3497_CR11","unstructured":"National Cancer Institute (2014) NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Bethesda, MD,"},{"issue":"14","key":"3497_CR12","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1002\/cncr.30031","volume":"122","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, Stein AS, Bargou RC, Grande Garcia C, Larson RA, Stelljes M, Gokbuget N, Zugmaier G, Benjamin JE, Zhang A, Jia C, Topp MS (2016) Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer 122(14):2178\u20132185. https:\/\/doi.org\/10.1002\/cncr.30031","journal-title":"Cancer"},{"issue":"2","key":"3497_CR13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcph.1006","volume":"58","author":"M Zhu","year":"2018","unstructured":"Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, Wolf A, Doshi S (2018) Blinatumomab pharmacodynamics and exposure-response relationships in relapsed\/refractory acute lymphoblastic leukemia. J Clin Pharmacol 58(2):168\u2013179. https:\/\/doi.org\/10.1002\/jcph.1006","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3497_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","volume":"26","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26(1):43\u201349","journal-title":"Curr Opin Pediatr"},{"issue":"14","key":"3497_CR15","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Bruggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"issue":"224","key":"3497_CR16","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225","journal-title":"Sci Transl Med"},{"issue":"16","key":"3497_CR17","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517. https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"6","key":"3497_CR18","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123\u20132138. https:\/\/doi.org\/10.1172\/JCI85309","journal-title":"J Clin Invest"},{"issue":"26","key":"3497_CR19","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125(26):4017\u20134023. https:\/\/doi.org\/10.1182\/blood-2014-12-580068","journal-title":"Blood"},{"key":"3497_CR20","doi-asserted-by":"crossref","first-page":"abstr 1589","DOI":"10.1182\/blood.V128.22.1589.1589","volume":"128","author":"M Klinger","year":"2016","unstructured":"Klinger M, Zugmaier G, Naegele V, Goebeler M, Brandl C, Bargou R, Kufer P (2016) Pathogenesis-based development of potential mitigation strategies for blinatumomab-associated neurologic events (NEs). Blood 128:abstr 1589","journal-title":"Blood"},{"issue":"10 suppl 1","key":"3497_CR21","doi-asserted-by":"crossref","first-page":"S52.006","DOI":"10.1212\/WNL.82.10_supplement.S52.006","volume":"82","author":"S Kranick","year":"2014","unstructured":"Kranick S, Phan G, Kochenderfer JN, Rosenberg SA, Nath A (2014) Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy. Neurology 82(10 suppl 1):S52.006","journal-title":"Neurology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3497-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T15:32:23Z","timestamp":1720625543000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3497-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3497"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3497-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Each center\u2019s institutional review board or ethics committee approved the study protocol and all patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ASS served as a speaker for Amgen Inc. and Celgene. GS has received clinical trial sponsorship from Amgen Inc. AZ, MZ, and ZZ are employees of and own stock in Amgen Inc. MST received grants and personal fees from Amgen Inc. RB and CJ have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}